# Enliven Therapeutics, Inc.: filings

ELVN · Nasdaq · CIK 1672619 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elvn.md) · [Financials](/companies/elvn/financials.md) · [Filings](/companies/elvn/filings.md) · [Insiders](/companies/elvn/insiders.md)

## Reports and events: 116 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 325, 144 157, 8-K 56, 3 44, SC 13G/A 22, 10-Q 20, SCHEDULE 13G/A 14, SC 13D/A 13, CORRESP 12, SC 13G 11, 4/A 10, S-8 9, 424B5 8, DEFA14A 8, UPLOAD 8, 10-K 6, DEF 14A 6, 425 5, EFFECT 5, SC 13D 5, 8-K/A 4, ARS 4, D 3, S-3 3, SCHEDULE 13D/A 3, 144/A 2, 424B3 2, PRE 14A 2, S-1/A 2, S-4/A 2, SCHEDULE 13G 2, SEC STAFF LETTER 2, 424B4 1, 8-A12B 1, CERT 1, DEFM14A 1, DRS 1, DRS/A 1, DRSLTR 1, PREM14A 1, S-1 1, S-3ASR 1, S-3MEF 1, S-4 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-14 | 16:39 ET | [8-K](/filings/0001193125-26-421761.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-421761 |
| 2026-08-05 | 16:15 ET | [10-Q](/filings/0001193125-26-335155.md) | Quarterly report, period 2026-06-30 | 0001193125-26-335155 |
| 2026-08-05 | 16:10 ET | [8-K](/filings/0001193125-26-335101.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-335101 |
| 2026-06-24 | 19:15 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000651.md) | Ownership report, active investor, amended | 0000947871-26-000651 |
| 2026-06-17 | 19:41 ET | [SCHEDULE 13D/A](/filings/0000947871-26-000636.md) | Ownership report, active investor, amended | 0000947871-26-000636 |
| 2026-06-12 | 16:55 ET | [8-K](/filings/0001193125-26-269635.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-269635 |
| 2026-06-11 | 08:09 ET | [8-K](/filings/0001193125-26-266731.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-266731 |
| 2026-06-10 | 17:32 ET | [8-K](/filings/0001193125-26-264085.md) | 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-264085 |
| 2026-05-07 | 16:17 ET | [10-Q](/filings/0001193125-26-211982.md) | Quarterly report, period 2026-03-31 | 0001193125-26-211982 |
| 2026-05-07 | 16:12 ET | [8-K](/filings/0001193125-26-211921.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211921 |
| 2026-04-27 | 16:06 ET | [DEF 14A](/filings/0001193125-26-182045.md) | Proxy statement, period 2026-06-09 | 0001193125-26-182045 |
| 2026-03-03 | 16:15 ET | [10-K](/filings/0001193125-26-088232.md) | Annual report, period 2025-12-31 | 0001193125-26-088232 |
| 2026-03-03 | 16:10 ET | [8-K](/filings/0001193125-26-088195.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-088195 |
| 2026-01-07 | 09:15 ET | [8-K](/filings/0001193125-26-005535.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-26-005535 |
| 2025-12-11 | 09:11 ET | [8-K](/filings/0001193125-25-315196.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-315196 |
| 2025-11-13 | 21:58 ET | [8-K/A](/filings/0001193125-25-278466.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-278466 |
| 2025-11-12 | 16:15 ET | [10-Q](/filings/0001193125-25-277619.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277619 |
| 2025-11-12 | 16:10 ET | [8-K](/filings/0001193125-25-277580.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-277580 |
| 2025-08-13 | 16:17 ET | [10-Q](/filings/0001193125-25-179845.md) | Quarterly report, period 2025-06-30 | 0001193125-25-179845 |
| 2025-08-13 | 16:15 ET | [8-K](/filings/0001193125-25-179837.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-179837 |
| 2025-06-25 | 16:05 ET | [8-K](/filings/0001193125-25-146874.md) | 5.07 Shareholder vote results | 0001193125-25-146874 |
| 2025-06-17 | 17:30 ET | [SCHEDULE 13D/A](/filings/0000947871-25-000616.md) | Ownership report, active investor, amended | 0000947871-25-000616 |
| 2025-06-16 | 06:44 ET | [8-K](/filings/0001193125-25-141085.md) | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-141085 |
| 2025-06-13 | 06:05 ET | [8-K](/filings/0001193125-25-140285.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-140285 |
| 2025-05-14 | 16:15 ET | [10-Q](/filings/0000950170-25-071412.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071412 |
| 2025-05-14 | 16:10 ET | [8-K](/filings/0000950170-25-071387.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071387 |
| 2025-04-28 | 16:05 ET | [DEF 14A](/filings/0001193125-25-100456.md) | Proxy statement, period 2025-06-24 | 0001193125-25-100456 |
| 2025-03-13 | 16:15 ET | [10-K](/filings/0000950170-25-038758.md) | Annual report, period 2024-12-31 | 0000950170-25-038758 |
| 2025-03-13 | 16:10 ET | [8-K](/filings/0000950170-25-038737.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-038737 |
| 2024-11-13 | 16:15 ET | [10-Q](/filings/0000950170-24-126332.md) | Quarterly report, period 2024-09-30 | 0000950170-24-126332 |
| 2024-11-13 | 16:10 ET | [8-K](/filings/0000950170-24-126323.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126323 |
| 2024-08-13 | 16:15 ET | [10-Q](/filings/0000950170-24-096239.md) | Quarterly report, period 2024-06-30 | 0000950170-24-096239 |
| 2024-08-13 | 16:10 ET | [8-K](/filings/0000950170-24-096204.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-096204 |
| 2024-07-29 | 18:12 ET | [SC 13D/A](/filings/0001104659-24-083627.md) | Ownership report, active investor, amended | 0001104659-24-083627 |
| 2024-06-18 | 17:12 ET | [8-K](/filings/0001193125-24-163507.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-24-163507 |
| 2024-05-29 | 16:06 ET | [8-K/A](/filings/0001193125-24-149141.md) | 5.02 Departure or appointment of officers or directors | 0001193125-24-149141 |
| 2024-05-20 | 16:55 ET | [SC 13D/A](/filings/0000947871-24-000499.md) | Ownership report, active investor, amended | 0000947871-24-000499 |
| 2024-05-14 | 16:15 ET | [10-Q](/filings/0000950170-24-059573.md) | Quarterly report, period 2024-03-31 | 0000950170-24-059573 |
| 2024-05-14 | 16:10 ET | [8-K](/filings/0000950170-24-059544.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059544 |
| 2024-04-26 | 16:05 ET | [DEF 14A](/filings/0001193125-24-117969.md) | Proxy statement, period 2024-06-18 | 0001193125-24-117969 |
| 2024-04-15 | 19:21 ET | [SC 13D/A](/filings/0001104659-24-047395.md) | Ownership report, active investor, amended | 0001104659-24-047395 |
| 2024-04-11 | 08:02 ET | [8-K](/filings/0001193125-24-092522.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-092522 |
| 2024-04-09 | 16:14 ET | [8-K](/filings/0001193125-24-090821.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-090821 |
| 2024-04-04 | 16:39 ET | [SC 13D/A](/filings/0000947871-24-000350.md) | Ownership report, active investor, amended | 0000947871-24-000350 |
| 2024-03-19 | 08:46 ET | [8-K](/filings/0001193125-24-070839.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-070839 |
| 2024-03-14 | 16:15 ET | [10-K](/filings/0000950170-24-031495.md) | Annual report, period 2023-12-31 | 0000950170-24-031495 |
| 2024-03-14 | 16:10 ET | [8-K](/filings/0000950170-24-031482.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-031482 |
| 2024-02-16 | 16:15 ET | [SC 13D/A](/filings/0001104659-24-024915.md) | Ownership report, active investor, amended | 0001104659-24-024915 |
| 2024-02-02 | 16:15 ET | [SC 13D/A](/filings/0001104659-24-010043.md) | Ownership report, active investor, amended | 0001104659-24-010043 |
| 2023-11-09 | 16:15 ET | [10-Q](/filings/0000950170-23-062080.md) | Quarterly report, period 2023-09-30 | 0000950170-23-062080 |

Page 1 of 3. [Older](/companies/elvn/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 27, 2026, 17:28 ET. No prices; not investment advice.